Bolze PharmD - Poxel SA COO CoFounder

All Insiders . France . 
Stock . Poxel SA . Stakeholders . Insider . Bolze PharmD
POXEL Stock  EUR 0.23  0.01  4.17%   

Insider

Bolze PharmD is COO CoFounder of Poxel SA
Phone33 4 37 37 20 10
Webhttps://www.poxelpharma.com

Poxel SA Management Efficiency

The company has return on total asset (ROA) of (0.3038) % which means that it has lost $0.3038 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (3.2337) %, meaning that it generated substantial loss on money invested by shareholders. Poxel SA's management efficiency ratios could be used to measure how well Poxel SA manages its routine affairs as well as how well it operates its assets and liabilities.
Poxel SA has accumulated 30.09 M in total debt with debt to equity ratio (D/E) of 25.5, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Poxel SA has a current ratio of 1.76, which is within standard range for the sector. Debt can assist Poxel SA until it has trouble settling it off, either with new capital or with free cash flow. So, Poxel SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Poxel SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Poxel to invest in growth at high rates of return. When we think about Poxel SA's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Philippe SchailleeSEB SA
N/A
Martin ZouharSEB SA
N/A
Joachim ReicheltEurofins Scientific SE
N/A
Isabelle PosthSEB SA
N/A
Sandra HoeylaertsEurofins Scientific SE
N/A
Timothy OostdykEurofins Scientific SE
N/A
Cyril BuxtorfSEB SA
57
Yvoine RemyEurofins Scientific SE
N/A
Valerie HanoteEurofins Scientific SE
57
Gabriel JuliaEurofins Scientific SE
N/A
Sylvain MorgeauBiomerieux SA
N/A
Petra KirchhoffSartorius Stedim Biotech
54
Gilles MartinEurofins Scientific SE
60
Giles PelissierSEB SA
N/A
Franois LacosteBiomerieux SA
N/A
Yasha MitrottiBiomerieux SA
N/A
Benedikt OrzelekSartorius Stedim Biotech
N/A
Cathy PianonSEB SA
N/A
Nathalie LomonSEB SA
52
John MackaySartorius Stedim Biotech
61
Philippe SumeireSEB SA
61
Poxel SA, a biopharmaceutical company, develops drugs for metabolic diseases with a primary focus on type II diabetes. The company was founded in 2009 and is headquartered in Lyon, France. Poxel SA operates under Pharmaceuticals And Biosciences classification in France and is traded on Paris Stock Exchange. It employs 33 people. Poxel SA (POXEL) is traded on Euronext Paris in France and employs 55 people.

Management Performance

Return On Equity-3.23
Return On Asset-0.3

Poxel SA Leadership Team

Elected by the shareholders, the Poxel SA's board of directors comprises two types of representatives: Poxel SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Poxel. The board's role is to monitor Poxel SA's management team and ensure that shareholders' interests are well served. Poxel SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Poxel SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Quentin Durand, Chief VP
Bolze PharmD, COO CoFounder
Sylvie Bertrand, VP HR
Pascale MD, CoFounder Affairs
Noah MBA, Exec Operations
Sophie HallakouBozec, CoFounder Communication
Elizabeth MBA, Corp Relations
MBA PharmD, CEO CoFounder
David MD, Ex Officer
Anne Renevot, Ex CFO

Poxel Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Poxel SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-3.23
Return On Asset-0.3
Operating Margin(134.99) %
Current Valuation51.26 M
Shares Outstanding30.83 M
Shares Owned By Insiders9.84 %
Shares Owned By Institutions23.08 %
Price To Earning13.09 X
Price To Book5.34 X
Price To Sales162.16 X

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
RSIRush Street Interactive
OKTAOkta Inc
BACBank of America

Additional Tools for Poxel Stock Analysis

When running Poxel SA's price analysis, check to measure Poxel SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poxel SA is operating at the current time. Most of Poxel SA's value examination focuses on studying past and present price action to predict the probability of Poxel SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poxel SA's price. Additionally, you may evaluate how the addition of Poxel SA to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY